Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib in Advanced Malignant Pheochromocytoma or Paraganglioma
NCT01635907Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jun 2012
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in pheochromocytoma and Paraganglioma (PGL), sponsored by Abramson Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Started Jun 2012; status: completed.
02
Drugs
dovitinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT01635907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01635907.